

# Answering the Most Common (Inpatient) Rheumatology Questions

16<sup>th</sup> Annual Rocky Mountain Hospital Medicine Symposium  
"CURBSIDE CONSULTATION TRACK"

Kevin Deane, MD  
Associate Professor of Medicine  
University of Colorado Denver

---

---

---

---

---

---

---

---

## Disclosures

None relevant

---

---

---

---

---

---

---

---

## Learning Objectives

- 1) Apply the diagnostic and therapeutic approach to acute crystalline arthropathy
- 2) Understand and implement a basic approach to suspected vasculitis
- 3) Identify common immediate approaches to controlling suspected severe systemic rheumatic disease
- 4) Understand approaches to management of chronic rheumatic disease medications in the inpatient setting

---

---

---

---

---

---

---

---

## Overview

- 1) Why is this patient's joint painful?
- 2) If it's crystals, how do I treat?
- 3) We think possibly vasculitis – what should we order?
- 4) What should we do for this sick patient while we wait for rheumatic disease work-up?
- 5) What do we do with this patient's rheumatic disease medications while they are in the hospital?

---

---

---

---

---

---

---

## Why is this patient's joint painful?

Key elements to the story:

- 1) Onset
- 2) Other findings (swelling and pain vs. just swelling)
- 3) Setting
- 4) Other joints! Toe hard to tap → knee easy (if you knew it was swollen)
- 5) Prior history
- 6) Imaging (sometimes helpful)
- 7) Joint fluid results ☺

---

---

---

---

---

---

---

## Critical points

What is the single best blood test to explain a 1-2 new swollen and painful joints?

Blood cultures

---

---

---

---

---

---

---

## Joint fluid analyses

### Testing

Gram stain  
Culture  
Cell count and differential  
Crystals

**Purple top/EDTA and syringe with cap. 2 mL (or more)**

### Anticoagulation

Level of anticoagulation doesn't typically matter  
INR <5 OK  
NOACs not a problem

### Operators:

Ortho, radiology, rheumatology, internal medicine

---

---

---

---

---

---

---

---

## Arthrocentesis and Joint Injection in Patients Receiving Direct Oral Anticoagulants

Jennifer C. Yui, MD; Carina Preskill, MD; and Laura S. Greenlund, MD, PhD

### Abstract

Anticoagulation is common in patients undergoing arthrocentesis and joint injections. Previous studies have established the safety of continuing anticoagulation with warfarin before joint aspirations/injections with only a small increased risk of bleeding, but no data are available regarding the use of direct oral anticoagulants (DOACs) and joint aspirations/injections. The objective of this study was to determine the rate of bleeding complications associated with arthrocentesis and joint injection in patients receiving DOACs. We performed a retrospective review of adult patients at Mayo Clinic in Rochester, Minnesota, who were being treated with DOACs and underwent outpatient joint aspiration and/or injection between October 1, 2010, and October 31, 2016. In 1050 consecutive procedures, there were no bleeding complications. Arthrocentesis and joint injections in patients receiving DOAC therapy are safe procedures, and there is no need to withhold anticoagulation treatment before the procedure.

© 2017 Mayo Foundation for Medical Education and Research • Mayo Clin Proc. 2017;92(8):1223-1226

---

---

---

---

---

---

---

---

## If it's crystals, how do I treat?

Depends

No renal, volume or GI issues = NSAIDs

If 1-2 joints, intra-articular steroids

If >2 joints, and/or issues preclude NSAIDs, systemic steroids

Colchicine possible but tricky and reasonable to avoid in acute crystalline arthritis  
NEVER IV (and you probably cannot get it)  
NEVER with cyclosporine (neuromuscular toxicity)

---

---

---

---

---

---

---

---

## Key article: inpatient gout

Curr Rheumatol Rep (2014) 16:458  
DOI 10.1007/s11926-014-0458-z

SURGERY AND PERIOPERATIVE CARE (CR MACKENZIE AND SM GOODMAN, SECTION EDITORS)

### Inpatient Gout: A Review

Mark C. Fisher · Michael H. Pillinger · Robert T. Keenan

---

---

---

---

---

---

---

---

## We think possibly vasculitis – what should we order?

Key elements to the story

What evidence do you have that there is end-organ damage from active obstructive vascular process?

What are acute levels of inflammation?  
ESR and CRP

---

---

---

---

---

---

---

---

## Things you can order for ‘broad’ look at vasculitis – but pretest probability is important!

### Labs

CBC, CMP, UA  
ESR, CRP  
ANA with panel  
C3 and C4  
Rheumatoid factor  
ANCA with MPO and PR3  
*Maybe antiphospholipid antibodies*

### Imaging

CTA and MRA not great resolution for vessels <5 mm

### Tissue

---

---

---

---

---

---

---

---

What should we do for this sick patient while we wait for rheumatic disease work-up?

**Depends on type and extent of illness**

**Catastrophic organ failure**

Methylprednisolone 1000 mg daily x 3 days then prednisone equivalent 1 mg/kg/day

**Modest organ failure**

Prednisone equivalent 1 mg/kg/day

---

---

---

---

---

---

---

---

What should we do for this sick patient while we wait for rheumatic disease work-up?

Other 'acute' therapies

**Plasma exchange**

If there is consideration for severe immune complex or antibody mediated diseases.

'immediate labs' include low complements and positive rheumatoid factor  
Clinical disease usually acute lung injury, renal failure, rashes

**IVIg**

Special situations usually neurological or for rheum, if want to avoid 'immunosuppression'

Need to watch for allergy and volume

---

---

---

---

---

---

---

---

What do we do with this patient's rheumatic disease medications while they are in the hospital?

Depends on why they are there

Only 'good' guidelines are for elective total knee and hip replacements which state that you can continue basically everything but stop injectables, infuseables and tofacitinib, and sometimes mycophenolate if the patient is doing well.

Everything else is good clinical judgement but a 'rule of thumb' is:

- a) OK to stop rheumatic therapies because there is not good evidence that if you stop it, the patient will lose long-term response
- b) Don't stop steroids but you can lower to prednisone 20 mg/day equivalent to provide adrenal coverage and minimize toxicity
- c) If infection a consideration, stop immunosuppression

---

---

---

---

---

---

---

---

**2017 American College of Rheumatology/  
American Association of Hip and Knee Surgeons  
Guideline for the Perioperative Management of  
Antirheumatic Medication in Patients With  
Rheumatic Diseases Undergoing Elective Total Hip  
or Total Knee Arthroplasty**

SUSAN M. GOODMAN,<sup>1</sup> BRYAN SPRINGER,<sup>2</sup> GORDON GUYATT,<sup>3</sup> MATTHEW P. ABDEL,<sup>4</sup>  
VENOD DAS,<sup>5</sup> MICHAEL GEORGE,<sup>6</sup> ORA GEWURZ-SINGER,<sup>7</sup> RON T. GILES,<sup>8</sup> BEVERLY JOHNSON,<sup>9</sup>  
STEVE LEE,<sup>10</sup> LISA A. MANDL,<sup>11</sup> MICHAEL A. MONT,<sup>12</sup> PETER SCULLO,<sup>13</sup> SCOTT SPOKER,<sup>14</sup>  
LOUIS STRYKER,<sup>15</sup> MARAT TURGUNBAEV,<sup>16</sup> BARRY BRAUSE,<sup>17</sup> ANTONIA F. CHEN,<sup>18</sup>  
BENNY GILBLAND,<sup>19</sup> MARK GOODMAN,<sup>20</sup> ARIANE HURELY-ROSENBLATT,<sup>21</sup> KYRIAKOS KIROU,<sup>1</sup>  
ELENA LOSINA,<sup>22</sup> RONALD MacKENZIE,<sup>23</sup> KALEB MICHAUD,<sup>24</sup> TED MIKULS,<sup>25</sup> LINDA RUSSELL,<sup>1</sup>  
ALEXANDER SAHL,<sup>26</sup> AMY S. MILLER,<sup>27</sup> JASVINDER A. SINGH,<sup>28</sup> and ADOLPH YATES<sup>29</sup>

---

---

---

---

---

---

---

---

Questions

[Kevin.Deane@ucdenver.edu](mailto:Kevin.Deane@ucdenver.edu)

UCHealth Docline: **1-844-285-4555**

<30% of inpatient settings have access to inpatient rheumatology  
consultation

WARNING: UCHealth doesn't pay for phone consults

---

---

---

---

---

---

---

---